Tryptophan immunoadsorption for multiple sclerosis and neuromyelitis optica relapses during pregnancy and breastfeeding

Tryptophan immunoadsorption for multiple sclerosis and neuromyelitis optica relapses during pregnancy and breastfeeding - TRIAS II Expect

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011770

Enrollment

Registered

2017-02-20

Start date

2014-11-17

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G35 G36

Interventions

Group 1: Patients treated with tryptophan immunoadsorption for MS or NMO relapse during pregnancy or breastfeeding as part of their standard medical care will be documented.

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Relapse of multiple sclerosis or neuromyelitis optica during pregnancy and breastfeeding. Use of tryptophan immunoadsorption as escalation therapy.

Exclusion criteria

Exclusion criteria: Patient doesn´t agree to be treated. Treating physician doesn´t want to participate in the documentation.

Design outcomes

Primary

Measure	Time frame
Efficacy of tryptophan immunoadsorption for MS and NMO relapse in pregnant and breatfeeding patients by comparing clinical-neurological symptoms before and immediately after the immunodasorption series.	—

Secondary

Measure	Time frame
Tolerability and safety of tryptophan immunoadsorption.	—

Countries

Germany

Contacts

Public ContactReinhard Klingel

Apherese Forschungsinstitut

afi@apheresis-research.org+49 221 406 3170

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026